Clinical Trial Update: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept and dose-finding study of XXB750 in heart failure was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• XXB750

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure | Phase 2 | Status: TERMINATED | Results posted: 2025-12-24